Logo image of BWV

BLUE WATER BIOTECH INC (BWV) Stock Fundamental Analysis

NASDAQ:BWV - Nasdaq - US09610B1089 - Common Stock - Currency: USD

0.1802  -0.01 (-5.16%)

After market: 0.19 +0.01 (+5.44%)

Fundamental Rating

0

BWV gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. BWV may be in some trouble as it scores bad on both profitability and health. BWV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BWV has reported negative net income.
BWV had a negative operating cash flow in the past year.
BWV Yearly Net Income VS EBIT VS OCF VS FCFBWV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

BWV's Return On Assets of -65.60% is on the low side compared to the rest of the industry. BWV is outperformed by 65.28% of its industry peers.
BWV has a worse Return On Equity (-178.61%) than 72.12% of its industry peers.
Industry RankSector Rank
ROA -65.6%
ROE -178.61%
ROIC N/A
ROA(3y)-75.82%
ROA(5y)N/A
ROE(3y)-128.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BWV Yearly ROA, ROE, ROICBWV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BWV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BWV Yearly Profit, Operating, Gross MarginsBWV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

BWV has more shares outstanding than it did 1 year ago.
BWV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BWV Yearly Shares OutstandingBWV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 5M 10M 15M
BWV Yearly Total Debt VS Total AssetsBWV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -3.60, we must say that BWV is in the distress zone and has some risk of bankruptcy.
BWV has a worse Altman-Z score (-3.60) than 60.77% of its industry peers.
A Debt/Equity ratio of 1.26 is on the high side and indicates that BWV has dependencies on debt financing.
BWV has a Debt to Equity ratio of 1.26. This is amonst the worse of the industry: BWV underperforms 81.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z -3.6
ROIC/WACCN/A
WACCN/A
BWV Yearly LT Debt VS Equity VS FCFBWV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 10M 20M

2.3 Liquidity

BWV has a Current Ratio of 0.54. This is a bad value and indicates that BWV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.54, BWV is not doing good in the industry: 95.33% of the companies in the same industry are doing better.
BWV has a Quick Ratio of 0.54. This is a bad value and indicates that BWV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of BWV (0.46) is worse than 94.99% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.46
BWV Yearly Current Assets VS Current LiabilitesBWV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

BWV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.75%.
EPS 1Y (TTM)-2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.31% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.13%
EPS Next 2Y13.39%
EPS Next 3Y5.31%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BWV Yearly EPS VS EstimatesBWV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BWV. In the last year negative earnings were reported.
Also next year BWV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BWV Price Earnings VS Forward Price EarningsBWV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BWV Per share dataBWV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.39%
EPS Next 3Y5.31%

More info and screens

0

5. Dividend

5.1 Amount

BWV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUE WATER BIOTECH INC

NASDAQ:BWV (12/21/2023, 8:10:00 PM)

After market: 0.19 +0.01 (+5.44%)

0.1802

-0.01 (-5.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2023-11-17/amc
Earnings (Next)N/A N/A
Inst Owners2.69%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap0
Analysts45
Price Target9.18 (4994.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.66%
Min EPS beat(2)-40.7%
Max EPS beat(2)-38.61%
EPS beat(4)2
Avg EPS beat(4)-9.54%
Min EPS beat(4)-40.7%
Max EPS beat(4)26.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)38.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-31.25%
EPS NY rev (1m)-23.58%
EPS NY rev (3m)-61.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS0.57
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.6%
ROE -178.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.82%
ROA(5y)N/A
ROE(3y)-128.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61300%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.46
Altman-Z -3.6
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y36.13%
EPS Next 2Y13.39%
EPS Next 3Y5.31%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1009.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-635.98%
OCF growth 3YN/A
OCF growth 5YN/A